About This Information

This section provides essential clinical context for the Cinqair Dosing Calculator. The information below details the dosing, administration, and safety considerations for reslizumab, intended for healthcare professionals. This content is for informational purposes and should not replace clinical judgment or official prescribing information.

Calculator Outputs Explained

The tool calculates key parameters based on the patient’s weight to facilitate accurate administration:

• Total Cinqair Dose (mg): The required dose calculated at 3 mg/kg and rounded to the nearest whole milligram.
• Volume to Withdraw (mL): The volume of Cinqair (10 mg/mL concentration) needed for the calculated dose.
• Number of Vials: The minimum number of 100 mg/10 mL vials required to prepare the dose.
• Total Infusion Volume (mL): The final volume after the calculated drug volume is added to a 50 mL bag of 0.9% Sodium Chloride.
• Recommended Infusion Rate (mL/hr): The range of infusion rates corresponding to an infusion time of 20 to 50 minutes.

How to Use the Calculator

The calculator is designed for straightforward use in a clinical setting:

1. Enter Patient Weight: Input the patient’s current body weight into the designated field.
2. Select Weight Unit: Choose kilograms (kg) or pounds (lbs) as the unit of measurement. The tool will automatically convert lbs to kg for the calculation.
3. Calculate: Click the “Calculate” button to generate the dosing and infusion parameters. All calculations are based on the guidelines found in the official prescribing information.

Dosing Overview

Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody (IgG4, kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype. The recommended dosage regimen is 3 mg/kg administered once every 4 weeks by intravenous infusion over 20 to 50 minutes. Doses should be recalculated if the patient’s weight changes.

Switching Therapies

There is no specific protocol for switching between biologic therapies for severe eosinophilic asthma. Any decision to switch a patient to or from Cinqair should be made by a specialist based on a comprehensive assessment of the patient’s clinical response, disease phenotype, side effect profile, and treatment goals. A suitable washout period may be necessary.

Missed Dose Protocol

If a planned dose of Cinqair is missed, the infusion should be administered as soon as the patient is available. The schedule for subsequent doses should be adjusted to maintain a 4-week interval between administrations.

Safety Alerts

The most common adverse reactions (incidence ≥2%) include oropharyngeal pain. Malignancy has been observed in clinical studies, but a causal relationship has not been established. Use with caution in patients with pre-existing helminth infections.

Frequently Asked Questions

1. What is the concentration of Cinqair?
   Cinqair is supplied in single-dose vials at a concentration of 100 mg/10 mL (10 mg/mL).
2. Why must Cinqair be diluted?
   Cinqair is a concentrate that must be diluted in a 50 mL infusion bag of 0.9% Sodium Chloride, USP, to prepare the final solution for intravenous infusion.
3. What is the recommended infusion time?
   The total diluted volume should be infused over 20 to 50 minutes. The infusion rate can be adjusted to meet this time frame.
4. Does the calculator adjust for renal or hepatic impairment?
   No, specific dose adjustments for renal or hepatic impairment are not recommended in the prescribing information, and the calculator does not account for this.
5. Can I administer other drugs through the same intravenous line?
   No. Cinqair should not be infused concomitantly in the same intravenous line with other agents.
6. How should the diluted solution be stored?
   The diluted solution should be used immediately. If not used right away, it can be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 16 hours.
7. What should I do if the patient’s weight is very high or low?
   The tool will provide a warning for weights outside the typical clinical trial range. Always use clinical judgment and refer to the official prescribing information when dosing patients at weight extremes.
8. Is Cinqair approved for pediatric patients?
   No, the safety and effectiveness of Cinqair have not been established in pediatric patients under 18 years of age.

References

• Cinqair (reslizumab) US Prescribing Information – U.S. Food and Drug Administration (FDA)
• Cinqaero (reslizumab) Summary of Product Characteristics – European Medicines Agency (EMA)
• Official Cinqair Healthcare Professional Website – Teva Pharmaceutical Industries Ltd.
• Reslizumab for treating severe eosinophilic asthma [TA479] – National Institute for Health and Care Excellence (NICE)